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Background: Alterations in the naive T cell subpopulations have been demonstrated in patients with T cell mediated
autoimmune disorders, reminiscent of immunological changes found in the elderly during immunosenescence,
including the switch from CD45RA + to CD45RO + T cells and decreased thymic function with increased compensatory
proliferative mechanisms, partly associated with latent Cytomegalovirus (CMV) infection. The present study was
aimed to investigate proportions of lymphocytes, their relation to CMV-seropositivity and the replicative history of
CD45RA + expressing T cells in Hashimoto’s thyroiditis (HT, n = 18) and healthy controls (HC, n = 70).
Methods: Proportions of peripheral T cells were investigated by flow cytometry. The replicative history was assessed by
T cell receptor excision circles (TRECs) and relative telomere length (RTL). Expression of CD62L was analyzed by
immunohistochemistry in thyroid sections. The role of CMV was assessed by serology, ELISPOT assay and in situ
hybridization.
Results: Our results demonstrated a significant increase of CD28-negative T cells, associated with CMV-seropositivity in
HT patients. HT showed abundant CD45RO + T cells with peripheral loss of CD62L-expressing CD8 + CD45RA + T cells,
the latter mainly depending on disease duration. CD62L was expressed in thyroid lymphocyte infiltrations. The
diagnosis of HT and within the HT group CMV-seropositivity were the main determinants for the loss of CD28
expression. RTL was not different between HC and HT. HT showed significantly lower TRECs in CD4 + CD45RA + T cells
compared to HC.
Conclusions: Patients with HT display a peripheral T cell phenotype reminiscent of findings in elderly persons or other
autoimmune disorders. Whether these mechanisms are primary or secondary to the immunological alterations of
autoimmune conditions should be investigated in longitudinal studies which may open research on new therapeutic
regimes for treatment of HT and associated autoimmune diseases.
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Naive T cell subpopulations are significantly altered in pa-
tients at the onset of T cell mediated autoimmune disorders,
such as diabetes mellitus type 1 and juvenile idiopathic arth-
ritis (JIA) [1,2]. These alterations are reminiscent of im-
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stated.of the immune system (immunosenescence), such as the
switch from the CD45RA+ to the CD45RO+T cell pheno-
type and a decrease in thymic function with increased com-
pensatory mechanisms [3,4]. Patients with rheumatoid
arthritis and JIA demonstrated increased CD28-negative T
cells, an erosion of telomere length as a marker of replicative
senescence and a loss of T cell receptor excision circles
(TRECs) as a parameter of thymic function and peripheral
proliferation of naive T cells [4]. TRECs are stable circular
DNA fragments that are created during T cell receptor re-
arrangement in the thymus [5,6] and have been described toLtd. This is an Open Access article distributed under the terms of the Creative
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cating during mitosis. Therefore, TREC numbers are as
much influenced by peripheral cell turnover as by the influx
of newly generated TREC-positive T cells from the thymus.
Latent Cytomegalovirus (CMV) infection was shown to
be a driving factor for T cell differentiation [7]. The major-
ity of CMV-specific T cells are included within the CD28-
negative T cell subpopulation. CMV-seropositive healthy
individuals demonstrated accelerated loss of CD28 expres-
sion [8], which was not seen in CMV-seropositive JIA
patients [9].
Hashimoto’s thyroiditis (HT) is an organ-specific auto-
immune disorder of the thyroid gland associated with dif-
fuse lymphoid infiltration, inflammatory destruction of
follicular cells and auto-antibodies against thyroid-specific
self-antigens [10-12]. However, the etiopathogenesis of HT
is far from being clearly understood [13]. Previous studies
have shown significant alterations of the peripheral B and
T cell subpopulations in HT [14] with a restricted T-cell
-receptor repertoire [15] and a suggested role of CD25+
regulatory T cells in balancing immune tolerance [16-20].
Thus, the present study was aimed to assess whether pa-
tients with HT show proportional alterations of the per-
ipheral T cell subpopulations as found in other T cell-
mediated autoimmune diseases. In order to investigate the
different T cell subpopulations, T cells were characterized
by expression of CD3 and either CD4 or CD8, B cells by
CD19 and natural killer (NK) cells by CD3-CD16/56+.
HLA-DR was used as an activation marker of T cells.
CD28 is a co-stimulatory molecule, which is lost through
differentiation of T cells. CD45RO mainly defines the
memory T cell subset, expression of CD45RA activated
naive T cells expressing the CD62L lymphocyte homing
factor [21]. High expression of CD25 in combination with
CD62L is characteristic for regulatory CD4+ T cells, and
in low amounts also for naive T cells.
A further aim was to investigate the replicative history
of CD45RA + expressing T cells by assessment of TRECs
and relative telomere length (RTL) and the association
with CMV-seropositivity. In our study, dilution of TRECs
was used to estimate the thymus output and the periph-
eral proliferative history of the CD45RA-expressing T cell
pool, which contains recent thymic emigrants (usually
high TREC numbers), pre-existing peripheral, naive T cells
(usually low TREC numbers due to peripheral replication
and dilution of TRECs) and a small amount of differenti-
ated effector T cells (usually TREC-negative).
Methods
Study population
Peripheral blood mononuclear cells (PBMCs) and sero-
logical samples were obtained from 18 patients with HT
and 70 healthy controls (HC) (Table 1). Diagnosis of HT
was based on clinical, serologic and ultrasound findingsaccording to the definitions of the American Thyroid As-
sociation. Within the HT group, 6 patients were newly di-
agnosed (disease duration <6 months). Those otherwise
healthy patients presented with either fatigue, hair loss or
weight gain and were advised to visit our outpatient
Department by their physician. HT patients with other
autoimmune diseases (e. g. diabetes type 1), other endocri-
nological diseases, malignancies, treatments known to in-
fluence immunological parameters (e. g. glucocorticoids),
immunodeficiency, pregnancy, acute infection in the last
two weeks, severe allergies needing local or systemic ther-
apies or administration of vaccines within the last four
weeks were not included into the study. Patients were
recruited from outpatient clinics at the Departments of
Pediatrics, Surgery or Nuclear Medicine, Medical Univer-
sity Innsbruck, Vienna and Wuerzburg in the study period
2011 to 2012. Immunologically healthy HC scheduled for
elective surgery (e. g. hernia or plastic surgery) without
any therapy, autoimmune disorders, endocrinologic dis-
eases, cancer or other immunological impairments were
recruited at the outpatient clinics at the Departments of
Pediatrics or Surgery, Medical University Innsbruck.
Serological measurements of thyroid-stimulating hor-
mone (TSH) (normal range: 0.35-3.50 μU/ml), free tri-
iodothyronine (fT3) (3.10-6.50 pmol/l), free thyroxine
(fT4) (10.30-21.90 pmol/l), thyroid peroxidase antibody
(TPOAb), thyrotropin-receptor antibody (TRAb), and
Tg antibodies (TgAb) were performed by ELISA (Roche
Diagnostics, Vienna, Austria) according to standard la-
boratory procedures at the Central Laboratory, Univer-
sity Hospital Innsbruck.
As CMV is well known to drive T cell differentiation
and alter proportions of peripheral lymphocyte subpopu-
lations [7-9], HC and HT were separated into CMV IgG
seropositive and seronegative subgroups. Anti-CMV IgG
and IgM were measured by ELISA (Enzygnost, Dade
Behring, Vienna, Austria) according to standard labora-
tory procedures at the Department of Hygiene and Med-
ical Microbiology, Medical University Innsbruck.
Fourteen HT patients had treatment with levothyroxine
(dosage 75–150 μg/day). Thyroidectomy was performed in
7 HT patients due to large nodular goiter in 2 cases and
suspect inactive nodules in 5 cases. These 7 patients had
been treated with levothyroxine in the last 6 months pre-
ceding blood sampling.
All patients or their legal guardians gave their written
informed consent to participate in the study. The study
was performed according to the Declaration of Helsinki
and was approved by the local ethical committee of the
Medical University Innsbruck.
Lymphocyte separation
PBMCs were isolated by using LymphoPrep™ (Axis
Shield, Oslo, Norway) according to manufacturer’s ins-
Table 1 Characteristics of the study populations
Groups (number;
male/female)
Age (years) Duration of
disease (years)
TSH (μU/ml) fT3 (pmol/l) fT4 (pmol/l) TPOAb/TRAb/TgAb
positive (number)
CMV IgG positive/
negative (number)
HC (70; 27/43) 13.7 ± 4.0
(14.6; 5.0 – 28.5)
n. a. 0.9 ± 0.3
(0.8; 0.7 – 1.2)
5.4 ± 1.0
(4.9; 4.7 – 6.6)
14.6 ± 1.9
(15.5; 12.3 – 15.9)
0/0/1 21/49
HT (18; 4/14) 14.1 ± 5.8
(13.6; 4.2 – 34.3)
3.1 ± 2.5
(3.3; 0.3-7.3)
6.9 ± 12.2
(2.1; 0.2 – 50.4) *
5.9 ± 1.2
(5.9; 4.1 – 8.8)
14.34 ± 3.1
(15.0; 8.4 – 19.1)
18/17/18 5/13
Values are given in mean ± standard deviation (median; range).
Abbreviations: Healthy controls (HC); Hashimoto’s thyroiditis (HT); thyroid peroxidase antibody (TPOAb); thyrotropin-receptor antibody (TRAb); Tg antibody (TgAb);
not applicable (n. a.).
Difference between HT and HC: * p < 0.05.
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(naive) T cells were separated by negative selection using
a naive CD4+ T cell isolation kit (Miltenyi Biotec,
Teterow, Germany), magnetic beads and Auto MACS
system with sterile columns (Miltenyi Biotec). Purity of
separated CD4+CD45RA+ T cells was checked using
4-colour flow cytometry (FACS-Calibur flow cytometer;
Becton Dickinson, Oxford, United Kingdom) and ranged
from 97 to 99%.
Lymphocyte phenotypes
Lymphocytes were characterized by staining with mono-
clonal mouse antibodies (mAbs) specific for CD4, CD8,
CD45RA, CD45RO, CD28, CD25 and CD62L labeled
with fluorochromes Fluoresceinisothiocyanat (FITC),
Phycoerythrin (PE), Peridinin-Chlorophyll (PerCP) or
Allophycocyanin (APC) (all antibodies were purchased
from BD Pharmingen, San Jose, California, USA) for 20
min at room temperature in the dark as described previ-
ously [2]. Results were expressed as percentage of gated
lymphocytes.
Quantification of TREC numbers
DNA was extracted from separated CD4+CD45RA+ T
cells using QIAamp DNA Mini Kit (Qiagen, Chatsworth,
California, USA). In order to remove contaminations,
which would interfere with polymerase chain reaction
(PCR), DNA was purified by ethanol-precipitation using
0.4M LiCl2 and 2.5-fold the volume 100% ethanol at
−20°C for 30 min. After centrifugation, the pellet was
washed twice with 70% ethanol to remove remaining
salts. The pellet was dissolved in nuclease-free water [2].
Signal-joint TREC concentrations were determined by
quantitative SYBR-green real-time PCR based on the
coding TREC sequence using an iCycler quantitative
RT-PCR system (BioRad Laboratories, Hercules, Canada)
and log2 dilutions of an internal standard as described
previously [2,6]. We designed primers to amplify a DNA
fragment 82 bp across the remaining recombination se-
quence δrec/ψalpha (5′-CAC ATC CCT TTC AAC
CAT GCT-3′ and 5′-GCC AGC TGC AGG GTT TAG
G-3′) (MWG Biotech AG, Ebersberg, Germany). PCR
reaction was run with 0.5 μg DNA, primers (12.5 μM/25μl) and 12.5 μl SYBR™ Green Supermix (Bio-Rad Labora-
tories, Hercules, Canada) in a final volume of 25 μl. Each
experiment was performed in duplicates. The thermal
cycling profile started with 4 minutes at 95°C. Repeating
cycles were performed 40 times at 95°C for 30 seconds
followed by 62°C for 30 seconds and 72°C for 30 sec-
onds. The process was followed by 1 cycle at 72°C for 30
seconds and finished with 70 cycles at 60°C for 10 sec-
onds. To identify the TREC quantification end products,
gelelectrophoresis of amplified TRECs was perfor-
med including the plasmid as positive control and a
TREC-negative control. To avoid bias by different num-
bers of naive T cells, TRECs were calculated in relation
to CD4 + CD45RA + T cell numbers [22].
Telomere length analysis
Determination of relative telomere length (RTL) was
performed to estimate the individual replicative history
of CD45RA-expressing T cells by calculating the ratio of
a quantitative PCR reaction product from the same sam-
ple using specific primers for telomeres and a single
copy gene as described previously [23,24]. Quantitative
PCR is the method of choice for determining telomere
length in small extractable quantities of DNA, as is the
case in our study. Due to limited sample size not all la-
boratory investigations regarding quantification of lym-
phocytes, RTL or TRECs could be performed in all
patients. In brief, separate PCR experiments were
performed for telomere (T) and 36B4 (a single copy
gene, S) in 96 well optical reaction plates with 20 μl of
each sample. A serially diluted standard was added to
each plate. The primer pair sequences for T were: tel1b
5′-CGG TTT GTT TGG GTT TGG GTT TGG GTT
TGG GTT TGG GTT-3′ and tel2b 5′-GGC TTG CCT
TAC CCT TAC CCT TAC CCT TAC CCT TAC
CCT-3′. Sequences for 36B4 were: 36B4 forward 5′-
CAG CAA GTG GGA AGG TGT AAT CC-3′ and 36B4
reverse 5′-CCC ATT CTA TCA TCA ACG GGT ACA
A-3′. Reagent mixture composition shared by T and S
PCR was 15 mM Tris–HCl (pH 8.0), 50 mM KCl, 200 μM
dNTP, 1% DMSO, 2.5 mM DTT, SYBR-Green I. Compos-
ition specific for the T PCR was 1.5 mM MgCl2, 1.5 Units
AmpliTaq Gold DNA polymerase and 450 nM of each
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PCR was 3.5 mM MgCl2, 0.75 Units AmpliTaq Gold
DNA polymerase, 300 nM 36B4 primer and 500 nM
36B4rev primer. Experiments were carried out on an ABI
Prism 7500 Sequence Detector. The thermal cycling pro-
file started with 15 minutes at 93°C to activate polymerase
for T PCR and 10 minutes at 95°C to activate polymerase
for the S PCR. Repeating cycles were performed 25 (T)
and 40 (S) times at 95°C for 15 seconds followed by 56°C
for 1 minute [1].
Immunohistochemistry
CD62L-expressing lymphocytes were identified after fix-
ation of thyroid tissue samples from the 7 thyroidecto-
mized HT patients with 4% neutral-puffered formalin by
staining with mouse-anti-human-CD62L antibody (MIB-1
clone; DAKO, Glostrup, Denmark) using an automated
immunostainer (Nexes, Ventana Medical Systems, Tucson,
AZ, USA) with 3,3-diaminobenzidine tetrahydrochloride
(DAB) A chromogen and counterstaining with Hema-
toxylin and Bluing Reagent. Slides were evaluated semi-
quantitatively by two independent investigators (MP and
AB) counting the number of CD62L + lymphocytes/100
lymphocytes/high power field (HPF) in at least 5 HPFs of
inflammatory hot spots. Healthy thyroid tissue sections of
5 donors without HT who were thyroidectomized due to
suspect inactive nodules were used as negative controls.
CMV in situ hybridization
Of the 7 thyroidectomized HT patients, 3 had a positive
serology for CMV. Paraffin-embedded samples from HT
patients were cut into 3 μm thick sections. Viral DNA was
detected using a Fluorescein-conjugated CMV probe
(34816 CMV probe) and Novocastra in situ hybridization
ISH detection kit (both from Leica Microsystems, London,
UK). Hybridization and detection of CMV was performed
according to the manufacturer’s recommendations. Slides
were counterstained with Mayers Hemalaun. A CMV-
infected colon tissue served as a positive control. The 4
CMV-seronegative HT patients served as negative controls.
CMV ELISPOT
CMV-specific reactivity of lymphocytes was determined in
three of the recently diagnosed and two other CMV-
seropositive HT patients and five CMV-seropositive HC
by using an Interferon-gamma (IFN-γ) ELISPOT analysis,
as described previously [25]. In brief, PBMCs were thawed
at 5 × 105 cells/well and stimulated with 0.5 μg/ml
peptivator CMV pp65 antigen (Miltenyi Biotec, Bergisch-
Gladbach, Germany), medium or phytohemagglutinin
(PHA) (3 μg/mL; Sigma, Taufkirchen, Germany) in anti-
human IFN-γ-precoated silent-screen 96-wells plates
(Mabtech) for 18 hours, developed and quantified using C.
T.L. ELISPOT reader software (Bonn, Germany). CMV-seronegative donors were used as negative controls. Re-
sults of CMV-specific IFN-γ-producing lymphocytes were
expressed in spot forming units/106 cells.
Statistics
The Kolmogorov-Smirnov test was applied to evaluate
the normality of distribution of different parameters.
Non-parametric Mann–Whitney U test was used to
compare HT and HC (SPSS, Version 19.0, Chicago, IL).
For multiple comparisons, Bonferroni’s correction was
applied. X2 test was used to compare dichotome vari-
ables between HT and HC, such as sex (male or female)
or CMV (IgG seropositive or seronegative). Spearman
Rank’s correlation coefficient was used to analyze corre-
lations of T cell subpopulations and age of subjects. To
identify independent factors for alterations in T cell pro-
portions, age, disease duration, CMV-seropositivity, sex
and HT disease were entered into a multivariate linear
regression model. A p < 0.05 was defined statistically
significant.
Results
Patients
No significant differences were present between the
groups regarding age (Table 1). There was no significant
age difference between 6 newly diagnosed HT patients
(mean 12.3 ± 1.9 years) and the other HT patients (mean
age 14.9 ± 7.2 years). In HT, 77.8% were female com-
pared to 61.4% in HC.
There was no significant difference between HT
(27.8%) and HC (30.0%) regarding frequency of individ-
uals positive for CMV-specific IgG (Table 1). One HT
patient and three HC were concomitantly positive for
CMV-specific IgM. Three of 6 newly diagnosed HT pa-
tients were CMV IgG positive (IgM negative).
Significantly higher TSH concentrations were found in
patients with HT compared to HC. Six HT patients had
TSH concentrations (5.4 to 50.4 μU/ml) above the nor-
mal range for age three of them belonged to the newly
diagnosed HT group. No differences were seen in free
serum thyroid hormones (Table 1). Five of 6 hypothyroid
HT patients were CMV-seronegative.
Lymphocyte subpopulations
Absolute lymphocyte counts were significantly lower in
HT patients compared to HC (Table 2). In HC, absolute
counts of lymphocytes (R = −0.679; p < 0.0001) and pro-
portions (R = −0.556; p < 0.001) negatively correlated with
age. These correlations were not seen in HT patients.
HT patients showed significantly lower proportions of
CD8+ T cells than HC, higher proportions of CD28-
negative CD8+ T cells (Figure 1A) and higher propor-
tions of CD45RO + T cells in both CD4+ and CD8+ T
cells (Figure 1B) (Table 2). Newly diagnosed HT patients
Table 2 Comparison of lymphocyte subpopulations in HT and HC
Lymphocyte subpopulation Healthy control (HC) Hashimoto’s thyroiditis (HT)
Number Mean ± standard deviation
(median; range)
Number Mean ± standard deviation
(median; range)
Lymphocytes absolute per μl 70 2508 ± 763 (2550; 960 – 4200) 18 1917 ± 659 (1794; 665 – 3264)***
Lymphocytes (% of white blood cells) 70 33.6 ± 10.9 (33.3; 15.0 – 62.0) 18 33.1 ± 12.5 (34.5; 15.0 – 54.0)
CD3+ (% of total lymphocytes) 66 68.3 ± 6.9 (68.0; 47.8 – 82.5) 18 68.8 ± 8.5 (69.2; 43.8 – 80.8)
CD4+ (% of total lymphocytes) 66 39.1 ± 6.9 (39.6; 25.8 – 51.1) 18 38.9 ± 7.1 (40.1; 21.5 – 51.6)
CD8+ (% of total lymphocytes) 66 27.8 ± 6.4 (26.5; 13.7 – 44.3) 18 24.1 ± 6.2 (23.3; 14.5 – 38.5)***
CD19+ (% of total lymphocytes) 66 16.1 ± 4.3 (15.3; 9.2 – 25.9) 18 18.6 ± 8.2 (16.1; 10.0 – 44.4)
CD3-CD16/56+ (% of total lymphocytes) 66 10.9 ± 5.9 (9.7; 3.8 – 33.7) 17 7.3 ± 3.5 (6.4; 3.3 – 15.0)
HLA-DR + (% of CD3+) 66 5.9 ± 2.8 (5.2; 1.8 – 12.4) 18 6.1 ± 2.5 (5.4; 2.4 – 11.3)
CD28- (% of CD4+) 65 1.5 ± 1.3 (1.3; 0.09 – 8.4) 16 1.1 ± 0.9 (0.9; 0.1 – 2.7)
CD28- (% of CD8+) 66 11.1 ± 13.7 (3.9; 0.15 – 61.7) 17 19.8 ± 13.3 (14.5; 4.8 – 52.3)***
CD45RO + (% of CD4+) 31 35.9 ± 12.9 (36.4; 1.4 – 59.4) 17 46.2 ± 12.9 (47.3; 23.2 – 74.7)**
CD45RO + (% of CD8+) 31 19.7 ± 10.6 (17.8; 0.07 – 48.3) 17 29.1 ± 13.2 (27.7; 11.9 – 57.8)***
CD45RA + CD62L + (% of CD4+) 64 61.1 ± 14.4 (60.9; 9.9 – 88.2) 17 54.4 ± 18.5 (53.6; 10.6 – 85.3)
CD45RA + CD62L + (% of CD8+) 63 61.6 ± 14.9 (64.2; 16.7 – 93.3) 17 51.9 ± 14.9 (55.3; 26.5 – 72.5)**
CD25 + CD62L + (% of CD4+) 64 22.8 ± 11.8 (20.8; 4.5 – 78.1) 17 23.6 ± 7.3 (21.5; 14.2 – 39.4)
Difference between HT and HC: *** p < 0.01, ** p < 0.02. Numbers of investigated samples from HC and HT are given in separate columns. For technical reasons
not all parameters were investigated in all HC and HT.
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the other HT patients (p < 0.05) (Figure 1A). Proportions
of CD45RA + CD62L + were lower in HT within the
CD8+ T cell pool compared to HC (Figure 1C). Newly
diagnosed HT patients had significantly lower propor-
tions of CD8 + CD45RA + CD62L + than the other HT
patients (p < 0.001) (Figure 1C).
Proportions of CD4 +CD25 +CD62L +T cells correlated
with age in HC (R = 0.278; p < 0.05) and HT (R = 0.529;
p < 0.05). No correlations between lymphocyte subpopula-
tions and hormone levels or thyroid hormone substitution
were seen. We could not find any significant differences be-
tween hypo- and euthyroid HT patients (Figure 1A-C).
CMV-seropositive HC showed higher proportions of
CD4 + CD28- T cells compared to CMV-seronegative
HC (Table 3). CMV-seropositive HT patients had signifi-
cantly higher proportions of CD8 + CD28- T cells com-
pared to CMV-negative HT and CMV-seropositive HC
(Table 3, Figure 2).
Including HT and HC, age, sex, disease duration and
CMV-seropositivity into a linear regression model, the
absolute lymphocyte counts (R = 0.493; p < 0.01) and the
CD28-negative T cell subpopulations (CD4+: R = 0.504;
p < 0.01; CD8+: R = 0.469; p < 0.01) were only influenced
by having HT. In the HT group, regression analysis re-
vealed an independent influence of disease duration
for lower CD8 + CD45RA + CD62L + T cells (R = 0.809;
p < 0.01). CMV-seropositivity was an independent factor
for higher proportions of CD28-negative CD8+ T cells
(R = 0.744; p < 0.01).RTL and TRECs
Relative telomere length was not different between HC
and HT (Table 4). Physiological shortening of telomeres
with advancing age, as found in HC (R = −0.513;
p < 0.0001), was not observed in HT patients. HT
showed significantly lower TRECs in CD4 + CD45RA +
T cells compared to HC (Table 4).
CMV-specific lymphocytes
In ELISPOT assay, CMV-seropositive HT patients and
HC showed similar numbers of IFN-γ-producing SFU
after unspecific stimulation with PHA (Figure 3A,C) or
CMV pp65 (Figure 3B,C). CMV in situ hybridization in
thyroid tissue of CMV-seropositive HT or HC did not
reveal any positive staining for CMV (Figure 4).
Expression of CD62L in thyroid glands of HT patients
Staining of CD62L in the thyroid tissue was positive in 5
of 7 HT patients, with a mean of 1.28 cells/100 cells/HPF,
2.56 cells/100 cells/HPF, 0.36 cells/100 cells/HPF, 1.8 cells/
100 cells/HPF and 0.08 cells/100 cells/HPF (Figure 5). No
difference regarding proportions of peripheral blood T cell
subpopulations was found between patients with high or
low CD62L + or CD62L-negative staining.
Discussion
Although it was suggested that HT may mainly result
from local autoimmune mechanisms in the thyroid gland
[12,13], changes in the peripheral T cell distribution were
detected in our study. Our results demonstrated a
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Figure 1 Percentages of CD28-negative (A), CD45RO + (B) and CD45RA + CD62L + (C) CD8+ T cells patients with Hashimoto’s Thyroiditis
(HT) and healthy controls (HC). Newly diagnosed HT patients are indicated as full circles. Hypothyroid patients are indicated by arrows.
Horizontal lines indicate the median. Differences between HT and HC: ** p < 0.02, *** p < 0.01.
Table 3 Comparison of proportions of lymphocyte subpopulations in CMV-seropositive HC and HT
Lymphocyte subpopulation Healthy controls (HC) Hashimoto’s thyroiditis (HT)
CMV negative (n = 33) CMV positive (n = 21) CMV negative (n = 12) CMV positive (n = 5)
CD28- (% of CD4+) 1.0 ± 0.8 (0.8; 0.1-3.0) 1.9 ± 1.6 (1.9; 0.2-8.4)## 1.0 ± 0.7 (0.9; 0.3-2.7) 1.4 ± 1.4 (1.4; 0.1-2.6)
CD28- (% of CD8+) 9.0 ± 9.4 (5.3; 0.5-32.2) 7.8 ± 14.1 (2.2; 0.2-61.7) 14.5 ± 6.1 (13.3; 4.8-26.4)*** 32.6 ± 17.7 (31.4; 12.3-52.3)** #
CD45RO + (% of CD4+) 32.5 ± 12.1 (31.5; 4.7-59.4) 30.7 ± 16.9 (38.4; 1.4-41.9) 44.2 ± 14.1 (43.6; 23.2-74.7)*** 50.9 ± 9.2 (47.5; 43.4-66.0)**
CD45RO + (% of CD8+) 18.7 ± 10.4 (15.7; 0.5-48.3) 14.3 ± 8.6 (15.7; 0.07-21.6) 28.5 ± 15.3 (25.6; 11.9-57.8)*** 30.5 ± 6.6 (27.7; 24.8-40.1)*
CD45RA + CD62L + (% of CD4+) 61.8 ± 17.6 (65.8; 9.9-88.2) 62.3 ± 12.6 (62.4; 27.5-80.8) 54.8 ± 20.2 (53.3; 10.6-85.3) 53.6 ± 15.5 (60.9; 27.3-66.0)
CD45RA + CD62L + (% of CD8+) 64.2 ± 15.0 (68.5; 16.7-83.6) 61.9 ± 15.5 (61.8; 32.2-93.3) 55.1 ± 14.69 (60.1; 26.5-72.5) 43.9 ± 13.9 (39.2; 31.4-61.8)
CD25 + CD62L + (% of CD4+) 22.4 ± 11.8 (20.5; 4.5-75.5) 23.7 ± 14.5 (19.7; 10.8-78.1) 25.8 ± 7.5 (24.3; 14.2-39.4) 18.4 ± 2.8 (19.4; 14.7-21.1) #
Values are given in mean ± standard deviation (median; range). Numbers (n) of investigated samples from HC and HT are given in brackets. For technical reasons,
lymphocyte populations were not investigated in all HC and HT.
Difference between HT and HC in the CMV-positive or CMV-negative groups: *** p < 0.01, ** p < 0.02, * p < 0.05.
Difference between CMV-positive and CMV-negative individuals in the HC or HT groups: ## p < 0.02, # p < 0.05.
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Figure 2 Percentages of CD28-negative CD8+ T cells in CMV-
seropositive (CMV+) or CMV-seronegative (CMV-) patients with
Hashimoto’s Thyroiditis (HT) and healthy controls (HC). Newly
diagnosed HT patients are indicated as full circles. Hypothyroid patients
are indicated by arrows. Horizontal lines indicate the median.
Differences between HT and HC: *** p < 0.05, ** p < 0.02, *** p < 0.01.
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http://www.biomedcentral.com/1472-6823/13/34significant increase of CD28-negative T cells in HT patients,
associated with CMV-seropositivity within the CD8+ T cell
subpopulation. A role of CD8+ T cells in thyroid inflamma-
tion, particularly in HT, was also clearly shown by others
[15,26-28]. Our results on CD28 expression differ from a
study in 35 children with autoimmune thyroiditis in whom
baseline CD28 expression was similar to healthy controls
[29]. However, after unspecific stimulation in vitro, CD28
expression decreased in autoimmune thyroiditis patients to
a much higher extend as seen in controls in that study [29],
which may underline the characteristic down-regulation of
CD28 seen in HT patients.
CMV is known to accelerate the increase of CD28-
negative T cells [8]. A similar association was also seen
in our HT group. These findings support the hypothesis
of accelerated differentiation of T cells with latent CMV
infections and an association with signs of prema-
ture immunosenescence known from patients with auto-
immune disorders [4,9,30,31]. Loss of CD28 is also seen
as a marker of replicative senescence of the immune
system [32]. However, the specificity of CD28-negativeTable 4 Relative telomere length (RTL) and T cell receptor ex
Parameter Healthy control (HC)
Number Mean ± standard deviation (m
RTL in CD4 + CD45RA+ 59 1.5 ± 0.9 (1.0; 0.03 – 4
RTL in CD8 + CD45RA+ 20 1.4 ± 0.6 (1.4; 0.6 – 2.
TRECs/ 1000 CD4 + CD45RA+ 11 2299 ± 205 (2278; 2105 –
TRECs/ 1000 CD8 + CD45RA+ 16 1206 ± 1633 (541; 164 –
Numbers of investigated samples from HC and HT are given in separate columns. For t
Difference between HT and HC: *** p < 0.01.CD8+ T cell subpopulations for CMV has to be demon-
strated in HT patients, as abundance of CMV-specific
CD8+ T cells has been so far shown only for healthy eld-
erly people [33]. In our study, HT patients demonstrated
similar CMV-specific lymphocyte reactivity compared
to healthy controls. Thus, causality between CMV and
loss of CD28-expression cannot be answered by our
study, although regression analysis revealed CMV-
seropositivity as an independent factor for higher pro-
portions of CD28-negative T cells within the HT group.
A primary role of CMV in induction of HT seems un-
likely, as a similar prevalence of CMV-specific serum
IgG was demonstrated for HT and HC and no expres-
sion of CMV-specific DNA was shown in histological
sections of CMV-seropositive HT patients. This was in
agreement with other studies [34,35] which could not
detect DNA of CMV in thyroid specimen of patients
with autoimmune thyroid diseases and showed a similar
CMV IgG seroprevalance in children with autoimmune
thyroid diseases [36]. It seems that CMV is rather in-
volved in a bystander activation of an already altered T
cell differentiation which is caused by in part unknown
autoimmune mechanisms [37]. Since both HT and CMV
are known to be related to immune dysfunction, it is
likely that in subjects affected by both conditions the
signs of immunological dysregulation are worse than
in others.
Regulatory T cells, mostly defined as CD4+ with high
expression of CD25, usually increase with age, but obvi-
ously have less suppressive function on inflammatory
mechanisms in some autoimmune diseases [31]. In our
cohort, age was the driving factor for enhancing CD25 +
CD62L + T cells. The role of CD25+ T cells in HT has
been discussed controversially [38,39]. An increased pro-
portion of CD4 + CD25+ cells was also found in patients
with autoimmune thyroiditis irrespective of age [38]. In
another study, the proportion of CD4 + CD25+ T cells
was not different between newly diagnosed and un-
treated autoimmune thyroiditis patients compared to
HC [39]. In those studies [15,38,39], HT patients
appeared to be heterogeneous regarding age, disease ac-
tivity and thyroid hormone production which makes
comparability difficult. In our cohort, the regulatory rolecision circles (TRECs)
Hashimoto’s thyroiditis (HT)
edian; range) Number Mean ± standard deviation (median; range)
.3) 17 1.2 ± 0.4 (1.1; 0.7 – 2.0)
9) 12 1.8 ± 2.9 (1.1; 0.08 – 9.4)
2514) 5 554 ± 248 (397; 133 – 730)***
2615) 4 333 ± 140 (360; 90 – 575)
echnical reasons, lymphocyte populations were not investigated in all HC and HT.
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Figure 3 Interferon-gamma-producing spot-forming-units (SFU) per 106 cells in patients with Hashimoto’s Thyroiditis (HT) and healthy
controls (HC). Peripheral blood mononuclear cells (PBMCs) were either stimulated with PHA (A) or with CMV pp65 antigen (B). A representative
example of ELISPOT analysis showed similar results for HT patients and HC (C). Negative controls were unstimulated. Experiments were
performed in duplicates.
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http://www.biomedcentral.com/1472-6823/13/34of these CD25 + CD62L + T cell fraction is unclear as the
use of these markers, CD25 and CD62L, cover both the
regulatory and the naive T cell phenotypes.
HT patients demonstrated peripheral loss of CD62L-
expressing CD8 + CD45RA + T cells, which was highly
significant in newly diagnosed HT patients. In order to
further explore the role of CD62L in our HT patients,
the expression of CD62L was investigated in histological
sections of seven HT patients who underwent surgery.
Five HT patients displayed significant CD62L expression
in follicular nodules within the afflicted thyroid gland,
suggesting a role of CD62L in homing of lymphocytes.
To measure peripheral turn-over of CD45RA-expressing
T cells, RTL and TRECs were assessed in some patients in
whom DNA of separated CD4 +CD45RA+ and CD8 +CD45RA +T cells was available. HT showed lower TREC
numbers in CD4 +CD45RA+T cells, with an additional
trend towards lower TREC numbers in CD8 +CD45RA +
T cells and shorter telomere length in CD8 +CD45RA+T
cells. TRECs are influenced by thymic output of recent
thymic emigrants and peripheral dilution by proliferation
of naive T cells [22]. Since the peripheral CD45RA +T cell
pool consists of predominantly naive T cells but also small
proportions of differentiated CD28-negative T cells [2], re-
duction of TRECs may be mostly caused by peripheral rep-
lication of CD4 +CD45RA+T cells. However, these
findings together with a trend to shorter RTLs and abun-
dance of CD28-negative T cells may support the hypothesis
of increased peripheral T cell turn-over and differentiation
of peripheral T cells in HT. Whether other mechanisms,
A B 
Figure 4 CMV in situ hybridization in thyroid sections of Hashimoto‘s thyroiditis (HT) patients. Characteristic infiltrate in a patient with HT
with oxyphilic follicular epithelium and surrounding lymphocytes without evidence of CMV DNA (A) compared to a positive control of CMV-
induced colitis (B). Examples of CMV positive cells are indicated by arrows.
A B
C D
Figure 5 CD62L-expression in thyroid sections of Hashimoto‘s thyroiditis (HT) patients. Representative example of CD62L +mononuclear
cell infiltrate in the thyroid gland of a patient with HT (A) compared to the thyroid gland of a healthy control (B) (20× magnification).
Representative example of CD62L-expression within a characteristic lymphoid follicle in the thyroid gland of a patient with HT (10×
magnification) (C). 40× magnification (D). Arrows indicate examples of CD62L +mononuclear cells.
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http://www.biomedcentral.com/1472-6823/13/34such as accelerated switching from CD45RA + to
CD45RO+, apoptosis of CD45RA +T cells or distribution
of specific T cell subpopulations to secondary lymphatic
organs or the thyroid gland (e. g. mediated by homing fac-
tors such as CD62L), play a role in diminishing TRECs
and in causing accumulation of CD45RO +memory and
effector T cells in the periphery remains to be investigated.
Conclusions
Patients with HT display a peripheral T cell phenotype
reminiscent of findings in elderly persons or other auto-
immune disorders, such as rheumatoid arthritis [3,40] or
JIA [4,31], with increased CD45RO +memory and CD28-
negative T cells, increased peripheral replication and al-
tered distribution of T cell proportions, such as CD62L-
expressing T cells with accumulation of CD62L + lympho-
cytes in the thyroid gland. CMV seems to accelerate T cell
differentiation by influencing CD28-negative T cell pro-
portions. Whether these mechanisms are primary or sec-
ondary to the immunological alterations of autoimmune
conditions should be investigated in longitudinal studies
which may open research on new therapeutic regimes for
treatment of HT and associated autoimmune diseases.
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